Anticoagulants Market

Report Overview

The global anticoagulants market was pegged at US$ 30.15 billion in 2020 and is expected to witness a CAGR of 7.3% during the forecast period.

Market Fundamentals

Anticoagulants, commonly known as blood thinners are drugs that help prevent formation of blood clot. They also keep existing blood clots from getting larger. A blood clot is a seal created by the blood to stop bleeding from wounds. While they are useful in stopping bleeding, they can block blood vessels and stop blood flowing to organs such as the brain, heart or lungs if they form in the wrong place. Anticoagulants are given to people at a high risk of getting clots, to reduce the chances of developing serious conditions such as strokes and heart attacks.

[8989]

Market Dynamics

The global anticoagulants market is mainly driven by the rising geriatric population; growing prevalence of deep vein thrombosis (DVT), atrial fibrillation (AF), and stroke; and growing demand for anticoagulant therapy. Furthermore, the growing adoption of novel oral anticoagulants (NOACs) is also likely to play a pivotal role in contributing to the growth of the market. However, the high cost of NOACs and stringent regulations are likely to restrain the market growth to a certain extent.

The COVID-19 pandemic had also resulted in significant spike in uptake of anticoagulants. This also intensified the pace of research to come up with novel anticoagulant agents to the market. Several clinical trials have been underway to assess many pipeline drugs with potential treatment to COVID-19 patients. Therefore, the COVID-19 pandemic has had a significant direct and indirect implications on this market.

Market Ecosystem

The global anticoagulants market has been analyzed from four perspectives: Drug Class, Application, and Region.

Anticoagulants Market by Drug Class

[4567]

Based on drug class, market has been segmented into novel oral anticoagulants (NOACs), vitamin K antagonist, heparin and low molecular weight heparin (LMWP), and others (calcium complexing agents, etc.). The novel oral anticoagulants (NOACs) segment dominated the market with the largest share in 2020, owing to its advantages over other drug classes such as their high efficacy in preventing stroke in AF; convenience of use; minor drug and food interactions; rapid onset and offset of action; and short half-life. Novel oral anticoagulants is a new anticoagulant drug class also characterized by shorter half like and use in prevention and treatment of myocardial infraction, pulmonary embolism, atrial fibrillation and deep vein thrombosis.

Product launches and approvals are also anticipated to open new growth opportunities in the anticoagulants market. Pradaxa was approved by the US FDA in June 2021 for the treatment of pediatric patients with venous thromboembolism. Increasing incidence of cardiovascular diseases, and technological advancements in the field of development of new formulations are therefore working in favor of the market growth. Conversely, great presence of generics, may negatively impact the market.

Anticoagulants Market by Application

Based on application, the anticoagulants market has been segmented into deep vein thrombosis (DVT), pulmonary embolism, myocardial infarction (MI), atrial fibrillation (AF), and others (cerebrovascular disease, defibrinated syndrome, hemodialysis etc.). The atrial fibrillation (AF) segment dominated the market with the largest share in 2020 owing to its high incidence rate and rising use of anticoagulants in AF to reduce the risk of stroke.

Anticoagulants Market by Region

Based on region, the global anticoagulants market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the anticoagulants market with the largest share in 2020, followed by Asia Pacific. The large share of North America in the global market can largely be attributed to its developed healthcare infrastructure; the rising prevalence of myocardial infarction (MI) and atrial fibrillation (AF); the rising demand for anticoagulation therapy; presence of prominent players in the region; and growing R&D activities.

Competitive Landscape

Some of the prominent players operating in the anticoagulants market are Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, Bayer AG, Daiichi Sankyo Company, Limited, Pfizer Limited., Bristol-Myers Squibb Company, Boehringer Ingelheim, Amphastar Pharmaceuticals, Inc., and Leo Pharma Inc., among others.

Strategic Developments

• In December 2020, Natco Pharma announced the launch of its novel oral anti-coagulant Rivaroxaban molecule, under brand RPIGAT in India. It would be available in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg
• In June 2020, Lonza announced a partnership agreement with Anthos Therapeutics, a biotech company created by Blackstone Life Sciences and Novartis, for the development and manufacturing of abelacimab, a novel factor XI and XIa antibody, which could address a range of thrombotic disorders
• In December 2019, the U.S. Food and Drug Administration approved the first generic versions of the powerful blood thinner Eliquis (apixaban) made by Mylan and Micro Labs
• In April 2018, the Janssen Pharmaceutical Companies of Johnson & Johnson announced its new worldwide collaboration with Bristol-Myers Squibb Company on a program to develop and commercialize Factor XIa (FXIa) inhibitors, including BMS-986177, for the prevention and treatment of major thrombotic conditions

Frequently Asked Questions About This Report